Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial
Jundong Wu, Jingxin Li, Jian Liu, Haomeng Wang, Guanghui Zhou, Jin Li, Dou Wu, Xiang Chen, Yan Feng, Xiaoyuan Qi, Xue Wang, Jin-Bo Gou, Tieliang Ma, Xiaoyun Yang, Li-feng Xu, Peng Wan, Tao Zhu, Zhongfang Wang, Fengcai Zhu, Ying Wang, Xiaomin Ma
Topics & Concepts
MedicineImmunogenicitySeroconversionAdverse effectVaccinationCohortRandomized controlled trialInternal medicineIncidence (geometry)Clinical trialImmunologyPediatricsAntibodyOpticsPhysicsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Impact on ReproductionAnimal Virus Infections Studies